Tenax Therapeutics said on 10 August 2026 that its Phase 3 LEVEL trial of oral levosimendan did not reach its primary endpoint, a result that changes the path for the drug’s development in pulmonary hypertension due to heart failure with preserved ejection fraction. The company also said the study missed its key secondary endpoint, leaving Tenax with a dataset that showed some signals but not the clean result it needed.
That is why Tenx Stock is being watched now: the trial result landed on the same day it was disclosed, and it immediately reset expectations around oral levosimendan. The primary goal was improvement in 6-minute walk distance versus placebo, while the key secondary measure was improvement in Kansas City Cardiomyopathy Questionnaire total symptom score. Tenax’s own line was blunt. The company said the study “did not reach its primary endpoint.”
Even so, the readout was not a simple miss across the board. Tenax said prespecified subgroup analyses showed a substantial beneficial treatment effect in patients with greater disease burden, while clinically meaningful changes were seen in predefined cardiac biomarker and pulmonary hemodynamic measures across the overall trial population. The company also said oral levosimendan was generally safe and well tolerated, with serious adverse events and adjudicated clinical worsening events balanced across treatment arms.
The friction is in the split between the headline result and the supporting signals. The trial failed the two endpoints that matter most for a registrational program, yet Tenax is pointing to the subgroup findings and the broader biomarker and hemodynamic data as evidence that the drug may still have a role in a narrower population. The company did not spell out the subgroup criteria behind the patients with greater disease burden, leaving the strongest hint in the package without the definition that would tell investors how widely it might apply.
Tenax now plans to request a Type C Meeting with the U.S. Food and Drug Administration and seek parallel scientific consultation from the European Medicines Agency. Orion Corporation, which described Tenax as its license partner, said the announcement was made as inside information through a stock exchange release at 14.05 EEST. The next step is no longer whether the program needs a reset; it is how much of the current development plan survives the regulator discussions and which parts will need to be revised.
